Laura Gravelsins

Laura Gravelsins

Auto-generated profile, based on publicly available information

Laura Gravelsins

Centre for Addiction and Mental Health, Toronto, Canada

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 May 2022 in Neurobiology of Aging
Verified
Journal Article
Closed access
NGNicole Gervais
Nicole Gervais
LGLaura Gravelsins
Laura Gravelsins
ABAlana Brown
Alana Brown
RRRebekah Reuben
Rebekah Reuben
LKLaurice Karkaby
Laurice Karkaby
GEGillian Einstein
Gillian Einstein

10 June 2021 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LGLaura Gravelsins
Laura Gravelsins
KDKatherine Duncan
Katherine Duncan
GEGillian Einstein
Gillian Einstein
Background: Despite the widespread use of oral contraceptives (OCs), and the well-documented influence of estrogens, notably 17β-estradiol (E2), on cognition, research relating OCs to working memory is limited and mixed. Two factors may contribute to these mixed findings: 1) pharmacokinetics of oral contraceptives, which drive fluctuations in synthetic hormone levels; and 2) genetic polymorphisms related to dopamine degradation and working memory, which interact with E2. This research investigated whether the pharmacokinetics of oral contraceptives, in concert with the single nucleotide polymorphism (Val158Met; rs4680) of the catechol-o-methyltransferase gene (COMT), influence working memory performance. Methods: University-age women taking and not taking OCs were tested for working memory and genotyped for COMT. If they were not taking OCs (n = 62), sessions occurred in the early follicular (low E2) and late follicular (high E2) phase. If they were taking OCs (n = 52), sessions occurred 1–2 hours after (high ethinyl estradiol, EE) and ~24 hours after (low EE) pill ingestion. Working memory was tested using the N-back, AX-CPT, Digit Span, and Digit Ordering Tasks. Data were analyzed using multilevel models with estrogen condition, COMT, and group as predictors, controlling for mood and practice effects. Results: For women taking OCs, time of pill ingestion did not influence performance. However, the subgroup with COMT val/val (low dopamine) were less accurate on 2-back lure trials than those with COMT met/met (high dopamine). For women not taking OCs, cycle phase moderated COMT’s influence on lure accuracy. When compared, women taking OCs had higher AX-CPT proactive control indices than those not taking OCs. Conclusion: These findings suggest that oral contraceptives are not detrimental for young women’s working memory and that they may increase proactive control. The more pronounced effects of COMT in women taking OCs suggests that, in women taking OCs, suppressed endogenous E2–not fluctuating EE levels–may be more relevant for working memory. Future studies are needed to differentiate effects of endogenous versus synthetic estrogens on working memory.

23 September 2025 in Neurology
Verified
Journal Article
Open access
TPTanvi A. Puri
Tanvi A. Puri
LGLaura L. Gravelsins
Laura L. Gravelsins
MAMadeline Wood Alexander
Madeline Wood Alexander
AMAndrew J. McGovern
Andrew J. McGovern
PGPaula Duarte Guterman
Paula Duarte Guterman
LGLiisa A.M. Galea
Liisa A.M. Galea
Menopause and menopausal hormone therapy (MHT) affect cognition, although existing studies are inconclusive. Age-related declines in executive functions, episodic memory, and prospective memory may be differentially sensitive to menopause age and MHT, due to variations in which brain regions are involved and their estrogen receptor density. Few studies have explored how menopause age and estradiol (E2)-based MHT by administration route affect these domains, a gap that this study addresses. This was a cross-sectional observational cohort study using baseline data from the Canadian Longitudinal Study of Aging. We separately examined the associations of age at menopause and E2-based MHT with performance in 3 cognitive domains: episodic memory, prospective memory, and executive functions. Linear regression models were used the test the association between cognitive performance and menopause variables. This cohort included 7,251 postmenopausal women (mean age at baseline 60.5 ± 10.2 years, mean age at menopause 50.5 ± 4.2 years), with models adjusted for age, education, and vascular risk. Earlier age at menopause was significantly associated with lower scores across all cognitive domains tested (episodic memory β = 0.050, 95% CI 0.027-0.072, p < 0.001; prospective memory β = 0.047, 95% CI 0.024-0.070, p < 0.001; executive functions β = 0.061, 95% CI 0.039-0.083; p < 0.001). However, for executive functions, an earlier age at menopause was associated with lower performance only in those with 4 or more children compared to those with no children (1-3 children β = 0.018-0.033, 95% CI -0.061 to 0.103, p > 0.350; 4+ children β = 0.215, 95% CI 0.133-0.296, p < 0.001) and there was a greater effect size among APOE ε4 carriers compared to non-carriers (β = 0.070, 95% CI 0.016-0.123, p < 0.001). We found that transdermal E2 was associated with higher episodic memory scores (transdermal E2 95% CI 0.294-0.533; no MHT 95% CI 0.196-0.247, p = 0.007, Cohen d = 0.303), whereas oral E2 was associated with higher prospective memory scores, compared with individuals who had never taken MHT (oral E2 95% CI 0.037-0.378, no MHT 95% CI -0.0359 to 0.009, p = 0.015, Cohen d = 0.283), Neither administration route significantly affected executive functions (p = 0.345). E2-based MHT efficacy depends on the route of administration and cognitive domain, underscoring the importance of considering MHT type. Although we cannot establish causality between menopause age, MHT use, and cognitive outcomes, this work provides clarity to inconsistencies in the literature and informs precision medicine approaches for cognitive aging. This study provides Class III evidence that use of E2-based MHTs was associated with higher episodic memory scores (transdermal E2 preparations) or higher prospective memory scores (oral E2 preparations) in postmenopausal women.

22 August 2024 in Hormones and Behavior
Verified
Journal Article
Open access
ABAlana Brown
Alana Brown
NGNicole J. Gervais
Nicole J. Gervais
LGLaura Gravelsins
Laura Gravelsins
JOJordan O'BYrne
Jordan O'BYrne
NCNoelia Calvo
Noelia Calvo
GEGillian Einstein
Gillian Einstein
Bilateral salpingo-oophorectomy (BSO; removal of ovaries and fallopian tubes) prior to age 48 is associated with elevated risk for both Alzheimer's disease (AD) and sleep disorders such as insomnia and sleep apnea. In early midlife, individuals with BSO show reduced hippocampal volume, function, and hippocampal-dependent verbal episodic memory performance associated with changes in sleep. It is unknown whether BSO affects fine-grained sleep measurements (sleep microarchitecture) and how these changes might relate to hippocampal-dependent memory. We recruited thirty-six early midlife participants with BSO. Seventeen of these participants were taking 17β-estradiol therapy (BSO+ET) and 19 had never taken ET (BSO). Twenty age-matched control participants with intact ovaries (AMC) were also included. Overnight at-home polysomnography recordings were collected, along with subjective sleep quality and hot flash frequency. Multivariate Partial Least Squares (PLS) analysis was used to assess how sleep varied between groups. Compared to AMC, BSO without ET was associated with significantly decreased time spent in non-rapid eye movement (NREM) stage 2 sleep as well as increased NREM stage 2 and 3 beta power, NREM stage 2 delta power, and spindle power and maximum amplitude. Increased spindle maximum amplitude was negatively correlated with verbal episodic memory performance. Decreased sleep latency, increased sleep efficiency, and increased time spent in rapid eye movement sleep were observed for BSO+ET. Findings suggest there is an association between ovarian hormone loss and sleep microarchitecture, which may contribute to poorer cognitive outcomes and be ameliorated by ET.

20 April 2023 in Frontiers in Neuroendocrinology
Verified
Journal Article
Closed access
LGLaura Gravelsins
Laura Gravelsins
SZSophia Zhao
Sophia Zhao
GEGillian Einstein
Gillian Einstein

1 October 2026 in Science
Verified
Journal Article
Closed access
LGLaura L. Gravelsins
Laura L. Gravelsins
MPMateja Perović
Mateja Perović
MAMadeline Wood Alexander
Madeline Wood Alexander
TSTallinn F. L. Splinter
Tallinn F. L. Splinter
AMAndrew McGovern
Andrew McGovern
LGLiisa A. M. Galea
Liisa A. M. Galea
Menopause is an important biological transition with up to 72 symptoms that shapes aging trajectories across organs and encompasses ~40% of the female lifespan. Although menopause awareness is increasing, research on strategies for menopause symptom management and optimizing health in the postmenopausal period is lacking. This Review highlights that menopause characteristics, such as type, timing, and symptom burden, influence health outcomes and later-life disease risk. Similarly, menopause hormone therapy comes in >200 varieties that differ by dose, formulation of estrogens and progestogens, and timing, each with their own distinct risk-benefit profiles. These distinctions are often missed in the literature but have considerable repercussions for outcomes. Optimized menopause care necessitates a precision medicine approach that considers menopause symptoms, genetics, and previous hormone exposures.